In primary membranous nephropathy, obinutuzumab increased the likelihood of complete remission vs. tacrolimus at 104 wk. (PubMed, Ann Intern Med) - Oct 6, 2026 - "GIM/FP/GP: [Formula: see text] Nephrology: [Formula: see text]."
Journal • Glomerulonephritis • Nephrology • Renal Disease
|
|
; Medha Airy; Wolfgang C Winkelmayer
|